5th Floor, Brigade Towers,
Financial District, Gachibowli,
Hyderabad - 500032,
The Acute Lymphoblastic Leukemia Therapeutics Market is segmented by Type of Cell (B-Cell, T-Cell, and Philadelphia Chromosome), Type of Therapy, and Geography.
Fastest Growing Market:
Acute lymphoblastic leukemia (ALL), also called as lymphoblastic leukemia, is one of the most common types of cancer, which spreads in the body through lymph nodes, spinal cord, liver, spleen, and central nervous system, among others. B-cell ALL, T-cell ALL, and Philadelphia chromosome-positive ALL (Ph+ ALL) are three of the most common primary types of ALL. B-cell ALL is the most common type. The treatment of patients with Ph+ ALL involves precise drugs which target the gene products.
|By Type of Cell|
|Philadelphia Chromosome: Positive (Ph+) and Negative (Ph-) ALL|
|By Type of Therapy|
|Stem Cell Transplantation|
Report scope can be customized per your requirements. Click here.
The American Cancer Association stated that chemotherapy is the main treatment for the people suffering from acute lymphoblastic leukemia (ALL), and it has three phases, such as remission, consolidation, and maintenance. Chemotherapy uses cytotoxic drugs for the destruction of cancer cells.
Amsacrine (NordMedica), cyclophosphamide (Baxter), and cytarabine (Pfizer) are some of the drugs that are used for chemotherapy in ALL. Global pharmaceutical players, such as Baxter International, and Pfizer, are providing these drugs.
It has been stated by the association named Indian Pediatrics that, chemotherapy is helping in the reduction of mortality rate due to ALL and acting as the most trusted treatment option available. Therefore, the rising importance of chemotherapy is contributing to the growth of this segment.
To understand key trends, Download Sample Report
North America is expected to dominate this market, due to the rising number of cases of this disease in the region, owing to genetic factors, environmental factors, and radiation. Moreover, favorable government policies, well-established healthcare infrastructure, and the presence of multinational companies make this region dominant in this market. Asia-Pacific is also expected to register a high CAGR during the forecast period, owing to several factors, such as high unmet clinical needs, huge patient pool, and the rising awareness about early diagnosis in emerging countries.
To understand geography trends, Download Sample Report.
The market for acute lymphoblastic leukemia is moderately competitive and consists of the big players as well as the mid-sized companies. Owing to the rising focus of most of the pharmaceutical companies on oncology, it is expected that few new small-sized companies will also penetrate the market in the near future.
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Rise in the Incidences of Acute Lymphoblastic Leukemia
4.2.2 Increasing Preference to Shift toward the Targeted Therapy Use
4.2.3 Increasing Initiatives Taken by the Government and Private Organizations
4.3 Market Restraints
4.3.1 Stringent Regulatory Pathways
4.3.2 High Cost Asscoiated with the Treatment
4.4 Porter's Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION
5.1 By Type of Cell
5.1.1 B-cell ALL
5.1.2 T-cell ALL
5.1.3 Philadelphia Chromosome: Positive (Ph+) and Negative (Ph-) ALL
5.2 By Type of Therapy
184.108.40.206 Hyper - CVAD Regimen
220.127.116.11 CALGB 8811 Regimen
18.104.22.168 Linker Regimen
22.214.171.124 Nucleoside Inhibitors
126.96.36.199 Other Types of Therapies
5.2.2 Targeted Therapy
5.2.3 Radiation Therapy
5.2.4 Stem Cell Transplantation
5.3.1 North America
188.8.131.52 United States
184.108.40.206 United Kingdom
220.127.116.11 Rest of Europe
18.104.22.168 South Korea
22.214.171.124 Rest of Asia-Pacific
5.3.4 Middle East & Africa
126.96.36.199 South Africa
188.8.131.52 Rest of Middle East & Africa
5.3.5 South America
184.108.40.206 Rest of South America
6. COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Bristol Myer Squibb Company
6.1.2 Celegene Corporation
6.1.3 Eisai Co Ltd
6.1.4 Erytech Pharma
6.1.5 F. Hoffmann-La Roche Ltd
6.1.6 Genmab AS
6.1.8 Novartis AG
6.1.9 Pfizer Inc.
6.1.10 Sanofi SA
6.1.11 SymBio Pharmaceuticals Limited
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
** Subject to Availability
**Competitive Landscape Covers - Business Overview, Financials, Products and Strategies, and Recent Developments